Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: A Gynecologic Oncology Group Study

Cancer Research

Volumn 63, Issue 6, 2003, Pages 1235-1241

  Farley, John ^f   Smith, Leia M ^a   Darcy, Kathleen M ^b   Sobel, Eugene ^b   O'Connor, Dennis ^c   Henderson, Benita ^d   Morrison, Larry E ^d   Birrer, Michael J ^e  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c Norton Healthcare   (United States)

^d ABBOTT LABORATORIES   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f Cancer Biology Department ^*

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLIN E; CYCLOPHOSPHAMIDE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CELL TYPE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; OVARY CARCINOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RACE;

AGED; CYCLIN E; EPITHELIAL CELLS; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0037444379     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Young, R., Perez, C., and Hoskins, W. Cancer of the ovary. In: V. T. DeVita, Jr., S. Hellman, and S. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, Ed. 4, pp. 1126-1263. Philadelphia: Lippincott, 1993.
2. Jemal, A., Thomas, A., Murray, T., and Thun, M. Cancer statistics, 2002. CA - Cancer J. Clin., 52: 23-47, 2002.
3. Kamb, A. Cell-cycle regulators and cancer. Trends Genet., 11: 136-140, 1995.
4. Hunter, T., and Pines, J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell, 79: 573-582, 1994.
5. 1 cyclin-Cdk protein kinase activity, is related to p21. Cell, 78: 67-74, 1994.
6. Craig, C., Wersto, R., Kim, M., Ohri, E., Li, Z., Katayose, D., Lee, S. J., Trepel, J., Cowan, K., and Seth, P. A recombinant adenovirus expressing p27(Kip1) induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells. Oncogene, 14: 2283-2289, 1997.
7. Millard, S. S., Yan, J. S., Nguyen, H., Pagano, M., Kiyokawa, H., and Koff, A. Enhanced ribosomal association of p27(Kip1) mRNA is a mechanism contributing to accumulation during growth arrest. J. Biol. Chem., 272: 7093-7098, 1997.
8. Polyak, K., Lee, M. H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., and Massague, J. Cloning of p27(Kip1), a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78: 59-66, 1994.
9. Fredersdorf, S., Burns, J., Milne, A. M., Packham, G., Fallis, L., Gillett, C. E., Royds, J. A., Peston, D., Hall, P. A., Hanby, A. M., Barnes, D. M., Shousha, S., O'Hare, M. J., and Lu, X. High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc. Natl. Acad. Sci. USA, 94: 6380-6385, 1997.
10. Keyomarsi, K., Conte, D., Jr., Toyofuku, W., and Fox, M. P. Deregulation of cyclin E in breast cancer. Oncogene, 11: 941-950, 1995.
11. Porter, P. L., Malone, K. E., Heagerty, P. J., Alexander, G. M., Gatti, L. A., Firpo, E. J., Daling, J. R., and Roberts, J. M. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med., 3: 222-225, 1997.
12. Mishina, T., Dosaka-Akita, H., Hommura, F., Nishi, M., Kojima, T., Ogura, S., Shimizu, M., Katoh, H., and Kawakami, Y. Cyclin E expression, a potential prognostic marker for non-small cell lung cancers. Clin. Cancer Res., 6: 11-16, 2000.
13. McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., and Clarke-Pearson, D. L. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med., 334: 1-6, 1996.
14. Agresti, A. Categorical data analysis: Wiley series in probability and mathematical statistics, pp. 42-43; 60-61. New York: John Wiley & Sons, Inc., 1990.
15. Kruskal, W. H., and Wallis, W. A. Use of ranks in one-criterion variance analysis. J. Am. Stat. Assoc., 53: 583-621, 1952.
16. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
17. Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep., 50: 163-170, 1966.
18. Cox, D. R. Regression models and life tables. J. R. Stat. Soc., 34: 187-220, 1972.
19. Hosmer, D. W., and Lemeshow, S. Applied survival analysis-regression modeling of time to event data, pp. 93-105; 158-195: 205-216. New York: John Wiley & Sons, Inc., 1999.
20. Klein, J. P., and Moeschberger, M. L. Survival analysis techniques for censored and truncated data, pp. 251-259. New York: Springer, 1997.
21. Session, D. R., Lee, G. S., Choi, J., and Wolgemuth, D. J. Expression of cyclin E in gynecologic malignancies. Gynecol. Oncol., 72: 32-37, 1999.
22. Sui, L., Tokuda, M., Ohno, M., Hatase, O., and Hando, T. The concurrent expression of p27(kip1) and cyclin D1 in epithelial ovarian tumors. Gynecol. Oncol., 73: 202-209. 1999.
23. Courjal, F., Louason, G., Speiser, P., Katsaros, D., Zeillinger, R., and Theillet, C. Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int. J. Cancer, 69: 247-253, 1996.
24. Marone, M., Scambia, G., Giannitelli, Giannitelli, C., Ferrandina, G., Masciullo, V., Bellacosa, A., Benedetti, P., and Muncuso, S. Analysis of cyclin E and CDK2 in ovarian cancer: gene amplification and RNA overexpression. Int. J. Cancer, 75: 34-39, 1998.
25. Schmider, A., Gee, C., Friedmann, W., Lukas, J. J., Press, M. F., Lichtenegger, W., and Reles, A. p21 (WAF1/CIP1) protein expression is associated with prolonged survival but not with p53 expression in epithelial ovarian carcinoma. Gynecol. Oncol., 77: 237-242, 2000.
26. Buttitta, F., Marchetti, A., Gadducci, A., Pellegrini, S., Morganti, M., Carnicelli, V., Cosio, S., Gagetti, O., Genazzani, A. R., and Bevilacqua, G. p53 alterations are predictive of chemoresistance and aggressive in ovarian carcinomas: a molecular and immunohistochemical study. Br. J. Cancer, 75: 230-235, 1997.
27. Sood, A. K., Sorosky, J. I., Dolan, M., Anderson, B., and Buller, R. E. Distant metastases in ovarian cancer: association with p53 mutations. Clin. Cancer Res., 5: 2485-2490, 1999.
28. Paley, P. J., Staskus, K. A., Gebhard, K., Mohanraj, D., Twiggs, L. B., Carson, L. F., and Ramakrishnan, S. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer (Phila.), 80: 98-106, 1997.
29. Moberg, K. H., Bell, D. W., Wahrer, D. C., Haber, D. A., and Hariharan, I. K. Archipelago regulates cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature (Lond.), 413: 311-316, 2001.
30. Richter, J., Wagner, U., Kononen, J., Fijan, A., Bruderer, J., Schmid, U., Ackermann, D., Maurer, R., Alund, G., Knonagel, H., Rist, M., Wilber, K., Anabitarte, M., Hering, F., Hardmeier, T., Schonenberger, A., Flury, R., Jager, P., Fehr, J., Schraml, P., Moch, H., Mihatsch, M., Gasser, T., Kallioniemi, O., and Sauter, G. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am. J. Pathol., 157: 787-794, 2000.